Efficacy and Safety of HuZhen Capsule for Treatment of Patients With Acute Gout
Status:
Unknown status
Trial end date:
2017-06-01
Target enrollment:
Participant gender:
Summary
This study is a multi-center, double-blind, randomized, parallel controlled trial. Patients
with acute gout will be enrolled and randomly allocated into 2 groups: HuZhen capsule
treatment group and Placebo control group. Randomization codes were established by the
biostatistician. Observe will be followed for 3 days (72 hours) after the onset. Change of
VAS score from baseline, proportion of improvement with damp-heat retention, change in
C-reactive protein (CRP) and erythrocyte sedimentation rate ( ESR) from baseline, change in
white blood cell count in whole blood cell analysis from baseline, and the number of adverse
events will be monitored and compared between each groups.